PSN-1 Cells
General information
| Description | The PSN-1 cell line is a human pancreatic adenocarcinoma model established from a primary pancreatic tumor. It is particularly notable for harboring amplifications of both the c-myc oncogene and the c-Ki-ras gene with a point mutation at codon 12. This mutation substitutes arginine for glycine (GGT to CGT), leading to an activated form of c-Ki-ras with transforming potential. PSN-1 retains the same molecular characteristics as the original tumor tissue, including a 50-fold amplification of c-myc and a 3- to 6-fold amplification of the mutated c-Ki-ras. These oncogenic amplifications are accompanied by significantly increased mRNA expression for both genes, suggesting their critical role in tumor progression. PSN-1 was derived through an unconventional process where frozen tumor tissues, stored for 1.5 years at -80°C without cryopreservation agents, were successfully transplanted into nude mice. From the resulting xenograft, the PSN-1 cell line was established and demonstrated stable oncogenic amplifications in vitro, mirroring those found in the original tumor and its metastatic lymph nodes. The cell line displays heterogeneous growth characteristics, with cells either adhering strongly as monolayers or growing in suspension. This dual behavior reflects a diverse cell population capable of adapting to different culture conditions. |
|---|---|
| Organism | Human |
| Tissue | Pancreas |
| Disease | Pancreatic adenocarcinoma |
| Applications | 3D cell culture |
| Synonyms | PSN1 |
Characteristics
| Age | Unspecified |
|---|---|
| Gender | Male |
| Ethnicity | East Asian |
| Morphology | Epithelial-like |
| Cell type | Epithelial cell |
| Growth properties | Adherent |
Regulatory Data
| Citation | PSN-1 (Cytion catalog number 305618) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1644 |
Biomolecular Data
| Mutational profile | Gene deletion: CDKN2A, Homozygous; Gene deletion: SMAD4, Homozygous; Mutation: KRAS, Simple, p.Gly12Arg (c.34G>C), Heterozygous; Mutation: TP53, Simple, p.Lys132Gln (c.394A>C), Homozygous |
|---|
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% heat-inactivated FBS |
| Dissociation Reagent | Accutase |
| Doubling time | 21 hours |
| Seeding density | 1-3*10^4/cm² |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|